GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
The Future of Drug Research Privacy: Navigating Evolving Regulations
Drug research is a critical endeavor that pushes the boundaries of medical science, leading to the development of life-saving treatments and therapies. However, this vital process involves collecting and analyzing sensitive personal data from research participants, raising important ethical and privacy concerns. As technology advances and data collection methods become more sophisticated, the need for robust privacy regulations in drug research is more pressing than ever.
Caregivers and Mental Health: The Unsung Heroes Need Support Too
Caregiving is an act of profound love and dedication, but it can also be a challenging journey filled with emotional, physical, and mental strain.
Why Trust is the Missing Ingredient in Medical Research
For decades, the world of medical research has faced a quiet but massive problem: most clinical trials don't look like the real world. While science moves faster than ever, the way we find people to participate in life-saving studies is stuck in the past. This is especially true for underrepresented communities—including Black, Hispanic, and Asian Americans
Real-World Evidence & Diagnostic Scaling
Focus: Translating clinical trial data into real-world medicine, and how AI can bridge the gap between expensive PET scans and scalable blood tests.
Ditching the Beta: A CFO’s Perspective on How Glassbury AI De-Risks Alzheimer’s Clinical Trials and Stabilizes the Cost of Capital
The contemporary biopharmaceutical ecosystem is currently navigating a profound systemic productivity crisis, frequently contextualized by "Eroom’s Law," wherein the cost of bringing a single novel therapeutic to market has surged exponentially to between $800 million and $1.4 billion.
The Hidden Danger: How AI Bias in Healthcare Can Harm Patients, and 15 Ways to Fix It
Artificial intelligence (AI) is rapidly moving from science fiction into everyday clinical settings and public health systems, especially with its accelerated use during the COVID-19 pandemic. These sophisticated applications, such as machine learning and deep learning, have enormous potential to revolutionize medicine, making care fairer and better overall. However, this powerful technology carries an enormous risk: if AI systems are not carefully designed, deployed, and monitored, they can deepen or reinforce existing health inequalities.
AI-Designed Oral GLP-1RA Shows Promise in Weight Loss
In the ongoing global health challenge of obesity and its associated conditions, the search for effective and convenient treatments is paramount. Recently, a significant breakthrough has emerged from China-based MindRank, a biotech company that has reported promising results from its Phase IIb clinical trial for an oral medication known as MDR-001.
The Dawn of Autonomous Science: Lila Sciences and the Future of Bioform Innovation
The bioplatform innovation company Flagship Pioneering unveiled Lila Sciences, marking a significant stride into the era of autonomous science. Lila Sciences aims to revolutionize scientific exploration by introducing Autonomous Science to the physical world, a concept that combines artificial intelligence (AI), robotics, and automated laboratories.
The Integration of Medidata Clinical Data Studio by ICON: A Paradigm Shift in Clinical Trial Management
In the dynamic and rapidly evolving landscape of clinical research, efficiency, accuracy, and speed are paramount. Clinical Research Organizations (CROs) are constantly seeking innovative solutions to streamline their processes, enhance data management, and accelerate the delivery of quality results.
How Artificial Intelligence is Reshaping Drug Target Identification
In the labyrinthine world of pharmaceutical research, the quest for effective new drugs often resembles a painstaking expedition through an uncharted wilderness. The initial and perhaps most critical phase of this journey is the identification of viable drug targets—specific molecules within the body that play a pivotal role in a disease's progression and can be modulated by therapeutic interventions. Traditionally, this process has been slow, expensive, and fraught with uncertainty. However, a revolutionary force is now transforming this landscape: Artificial Intelligence (AI). By harnessing the power of vast datasets and sophisticated algorithms, AI is rapidly reshaping the field of drug target identification, offering unprecedented speed, precision, and potential.